Ansamitocin P-3 is primarily utilized in the field of cancer research and treatment due to its potent antitumor properties. It functions as a microtubule inhibitor, disrupting the formation of the mitotic spindle during cell division, which leads to the arrest of cancer cell proliferation. This compound is particularly effective in targeting and killing cancer cells, making it a valuable component in the development of antibody-drug conjugates (ADCs). These ADCs are designed to deliver the cytotoxic agent directly to tumor cells, minimizing damage to healthy tissues. Additionally, Ansamitocin P-3 has been studied for its potential in overcoming drug resistance in certain types of cancer, offering a promising avenue for more effective therapeutic strategies.